Non-small cell lung cancer

News

FDA won't back Lilly's PD-1 antibody based on Chinese data a...

The FDA has dropped a bomb on Eli Lilly's marketing application for cancer immunotherapy sintilimab ahead of an advisory committee meeting due to take place on Thursday.

News

Chasing Roche, Merck unveils adjuvant lung cancer data for K...

Merck & Co's Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but was leapfrogged by Roche's Tecentriq in the early-stage, adjuvant trea

News

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years of effort to bring a drug to market that inhibits KRAS – a cancer target that for

News

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status.

News

FDA gives Daiichi Sankyo's HER3 drug a breakthrough tag

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer.

News

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

Novartis has joined the ranks of big pharma companies developing TIGIT-targeted drugs for cancer, and found its candidate in an existing partner, Chinese biotech BeiGene.

FDA won't back Lilly's PD-1 antibody based on Chinese data a...

Chasing Roche, Merck unveils adjuvant lung cancer data for K...

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

FDA gives Daiichi Sankyo's HER3 drug a breakthrough tag

Novartis taps immuno-oncology partner BeiGene for TIGIT drug

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Non-small cell lung cancer

Editor's Picks